Takeshi Fujii

Prof. Takeshi Fujii


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
TFTakeshi Fujii
Takeshi Fujii
YTYuki Takada-Takatori
Yuki Takada-Takatori
KKKoichiro Kawashima
Koichiro Kawashima
Lymphocytes possess all the components required to constitute an independent, non-neuronal cholinergic system. These include acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively). ACh modifies T and B cell function via both mAChR- and nAChR-mediated pathways. Stimulation of lymphocytes with the T cell activator phytohemagglutinin, protein kinase C activator phorbol ester, or cell surface molecules enhances the synthesis and release of ACh and up-regulates ChAT and/or M5 mAChR gene expression. Furthermore, animal models of immune disorders exhibit abnormal lymphocytic cholinergic activity. The cholesterol-lowering drug simvastatin attenuates the lymphocytic cholinergic activity of T cells by inhibiting LFA-1 signaling in a manner independent of its cholesterol-lowering activity. This suggests that simvastatin exerts its immunosuppressive effects in part by modifying lymphocytic cholinergic activity. Nicotine, an active ingredient of tobacco, ameliorates ulcerative colitis but exacerbates Crohn’s disease. Expression of mRNAs encoding the nAChR α7 and α5 subunits are significantly diminished in peripheral mononuclear leukocytes from smokers, as compared with those from nonsmokers. In addition, long-term exposure of lymphocytes to nicotine reduces intracellular Ca2+ signaling via α7 nAChR–mediated pathways. In fact, studies of humoral antibody production in M1/M5 mAChR–deficient and α7 nAChR–deficient animals revealed the role of lymphocytic cholinergic activity in the regulation of immune function. These results provide clues to understanding the mechanisms underlying immune system regulation and could serve as the basis for the development of new immunomodulatory drugs.

Verified
Journal Article
Open access
PDF file
MMMasato Mashimo
Masato Mashimo
YMYasuhiro Moriwaki
Yasuhiro Moriwaki
HMHidemi Misawa
Hidemi Misawa
KKKoichiro Kawashima
Koichiro Kawashima
TFTakeshi Fujii
Takeshi Fujii
Acetylcholine (ACh) is the classical neurotransmitter in the cholinergic nervous system. However, ACh is now known to regulate various immune cell functions. In fact, T cells, B cells, and macrophages all express components of the cholinergic system, including ACh, muscarinic, and nicotinic ACh receptors (mAChRs and nAChRs), choline acetyltransferase, acetylcholinesterase, and choline transporters. In this review, we will discuss the actions of ACh in the immune system. We will first briefly describe the mechanisms by which ACh is stored in and released from immune cells. We will then address Ca2+ signaling pathways activated via mAChRs and nAChRs on T cells and B cells, highlighting the importance of ACh for the function of T cells, B cells, and macrophages, as well as its impact on innate and acquired (cellular and humoral) immunity. Lastly, we will discuss the effects of two peptide ligands, secreted lymphocyte antigen-6/urokinase-type plasminogen activator receptor-related peptide-1 (SLURP-1) and hippocampal cholinergic neurostimulating peptide (HCNP), on cholinergic activity in T cells. Overall, we stress the fact that ACh does not function only as a neurotransmitter; it impacts immunity by exerting diverse effects on immune cells via mAChRs and nAChRs.

1 November 2012 in Life Sciences
Verified
Journal Article
Closed access
TFTakeshi Fujii
Takeshi Fujii
YTYuki Takada-Takatori
Yuki Takada-Takatori
KKKoichiro Kawashima
Koichiro Kawashima

1 March 2012 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
TFTakeshi Fujii
Takeshi Fujii
YTYuki Takada-Takatori
Yuki Takada-Takatori
KHKazuhide Horiguchi
Kazuhide Horiguchi
KKKoichiro Kawashima
Koichiro Kawashima

1 March 2017 in Life Sciences
Verified
Journal Article
Closed access
MMMasato Mashimo
Masato Mashimo
YIYukari Iwasaki
Yukari Iwasaki
SIShoko Inoue
Shoko Inoue
SSShoko Saito
Shoko Saito
KKKoichiro Kawashima
Koichiro Kawashima
TFTakeshi Fujii
Takeshi Fujii

1 April 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
MMMasato Mashimo
Masato Mashimo
STShiori Takeshima
Shiori Takeshima
HOHiromi Okuyama
Hiromi Okuyama
AMAyako Matsurida
Ayako Matsurida
MMMami Murase
Mami Murase
TFTakeshi Fujii
Takeshi Fujii